251 related articles for article (PubMed ID: 20440266)
1. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
2. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.
Chen JL; Limnander A; Rothman PB
Blood; 2008 Feb; 111(3):1677-85. PubMed ID: 18042805
[TBL] [Abstract][Full Text] [Related]
3. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
5. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes.
Yang J; Wang J; Chen K; Guo G; Xi R; Rothman PB; Whitten D; Zhang L; Huang S; Chen JL
Cancer Res; 2013 Aug; 73(15):4898-908. PubMed ID: 23749639
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
Zenz T; Döhner K; Denzel T; Döhner H; Stilgenbauer S; Bullinger L
Br J Haematol; 2008 May; 141(5):742-3. PubMed ID: 18410456
[No Abstract] [Full Text] [Related]
7. AKT1(E17K) in human solid tumours.
Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
[TBL] [Abstract][Full Text] [Related]
8. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
[TBL] [Abstract][Full Text] [Related]
9. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
[TBL] [Abstract][Full Text] [Related]
11. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
[TBL] [Abstract][Full Text] [Related]
12. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
13. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
14. Pim-1 regulates cardiomyocyte survival downstream of Akt.
Muraski JA; Rota M; Misao Y; Fransioli J; Cottage C; Gude N; Esposito G; Delucchi F; Arcarese M; Alvarez R; Siddiqi S; Emmanuel GN; Wu W; Fischer K; Martindale JJ; Glembotski CC; Leri A; Kajstura J; Magnuson N; Berns A; Beretta RM; Houser SR; Schaefer EM; Anversa P; Sussman MA
Nat Med; 2007 Dec; 13(12):1467-75. PubMed ID: 18037896
[TBL] [Abstract][Full Text] [Related]
15. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells.
Salhia B; Van Cott C; Tegeler T; Polpitiya A; Duquette RA; Gale M; Hostteter G; Petritis K; Carpten J
Hum Mutat; 2012 Aug; 33(8):1216-27. PubMed ID: 22505016
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
He Y; Zheng J; Hu Y; Xiao H; Liu J; Li X; Du W; Chen X; Hu Y; Huang S
Eur J Haematol; 2010 Jan; 84(1):87-8. PubMed ID: 19744127
[No Abstract] [Full Text] [Related]
18. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
Landgraf KE; Pilling C; Falke JJ
Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
[TBL] [Abstract][Full Text] [Related]
19. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
20. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
